Search Results for 'Ldl-Cholesterol'

Ldl-Cholesterol published presentations and documents on DocSlides.

PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
Looking to FOURIER:  What do the trials tell us about LDL lowering and cardiovascular events?
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
by min-jolicoeur
NICE –CG 181 Continuum of CVD Risk and its trea...
Abnormalities of LDL metabolism
Abnormalities of LDL metabolism
by briana-ranney
Physiology, pathophysiology and treatments. Under...
SWL lipid management guideline update- Highlights
SWL lipid management guideline update- Highlights
by finley
 . Pedro Bandeira. Specialist Pharmacist- Cardiov...
Update on Clinical Trials:
Update on Clinical Trials:
by adia
How Will This Affect Practice in the Future?. Pame...
Non-obese rheumatoid arthritis patients
Non-obese rheumatoid arthritis patients
by valerie
withlow. low-density lipoprotein have higher coro...
Putting Your Skills to the Test
Putting Your Skills to the Test
by deborah
Which ONE of the following statements regarding th...
New concepts and guidelines in the management of LDL-c and CV Risk:
New concepts and guidelines in the management of LDL-c and CV Risk:
by cappi
Need for early intervention. Prof. . Ulf . Landmes...
SocietyPositionStatementCanadianCardiovascularSocietyPositionStatement
SocietyPositionStatementCanadianCardiovascularSocietyPositionStatement
by elizabeth
CanadianJournalofCardiology34(2018)1553 Receivedfo...
CLEVELAND CLINIC JOURNAL OF MEDICINE      VOLUME 73  NUMBER 1       J
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J
by iris
CHRISTOPHER SIBLEY,MDDepartment of Cardiology,John...
CLINICAL PRACTICE
CLINICAL PRACTICE
by mia
USTRALIAN FAMILY Vol. 37, No. 7, July 2008 ichard ...
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
by sophie
Bilal Ilanbey Meral Kayikcioglu Ebru Demirel Sez...
6701 Carnegie Ave  Suite 500  Cleveland OH 44103  p 8663589828
6701 Carnegie Ave Suite 500 Cleveland OH 44103 p 8663589828
by gelbero
ApoE genotype can affect:Response to treatment wit...
ODYSSEY FH I and II In FH I:
ODYSSEY FH I and II In FH I:
by Aquamarine
From baseline to 24 weeks, the change in . LDL-C: ...
Statin Side effects   Active treatment
Statin Side effects   Active treatment
by ximena
Control. Relative risk. Absolute Effect. (per thou...
DYSLIPIDEMIA IN DIABETES
DYSLIPIDEMIA IN DIABETES
by esther
MAHTAB NIROOMAND M.D.. Assistant professor of End...
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
by mediumgeneral
Pesticide Exposed Workers. Nor Zamzila Abdullah. ...
Rational Order of Laboratory Tests in Cardiovascular Diseases
Rational Order of Laboratory Tests in Cardiovascular Diseases
by carneos
Sedighe. . S. adat . Ghorashi. . MD. Family Medic...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by pressio
Implications from the SHARP trial. Dr. Christina R...
 Diabetes and Dyslipidemia
Diabetes and Dyslipidemia
by danika-pritchard
2013 ACC/AHA Guideline on the. Treatment of Blood...
PCSK-9 Inhibitors Paul J
PCSK-9 Inhibitors Paul J
by tatyana-admore
PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
New developments in lipid management
New developments in lipid management
by pasty-toler
CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP....
Update:  Lipid Guidelines
Update: Lipid Guidelines
by yoshiko-marsland
DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. ...
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
by pamella-moone
Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...
Risk factors in  heart disease
Risk factors in heart disease
by faustina-dinatale
Optimizing . patient care. William Cromwell, MD, ...
FOURIER F urther cardiovascular
FOURIER F urther cardiovascular
by trish-goza
OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...
Triglycerides and Risk for Atherothrombosis
Triglycerides and Risk for Atherothrombosis
by briana-ranney
Thomas Dayspring, MD, FACP. Clinical Assistant Pr...
협심증  ( 狹心症 )
협심증 ( 狹心症 )
by lois-ondreau
Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by pasty-toler
Developed by . Ms. . Shawna . Morrison, Dr. Judit...
0 Circulation and Gas Exchange
0 Circulation and Gas Exchange
by tatyana-admore
The fluid that moves around in the circulatory sy...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by marina-yarberry
Implications from the SHARP trial. Dr. Christina ...
Switch to RAL-containing regimen
Switch to RAL-containing regimen
by josephine
Canadian Study. CHEER. Montreal Study. EASIER. SWI...
American Heart Association, November 13, 2023, Philadelphia, PA
American Heart Association, November 13, 2023, Philadelphia, PA
by bella
Inflammation and Cholesterol as Predictors of Card...
Cardiovascular Disease in HIV
Cardiovascular Disease in HIV
by stella
Steven K. Grinspoon, MD. Professor of Medicine. Ha...
Biochemistry Mayur V. Patel
Biochemistry Mayur V. Patel
by eliza
Consultant in Chemical Pathology/Metabolic Medicin...